Why SLEEP 2026 Matters for Inspire Medical Systems Stock

Inspire Medical Systems (INSP) used the SLEEP 2026 conference to put fresh clinical and technology data in front of sleep specialists, highlighting how its Inspire therapy compares with Continuous Positive Airway Pressure and no treatment.

For investors watching the stock, the event is less about the booth number in Baltimore and more about what this package of results could mean for the company’s position in obstructive sleep apnea treatment and potential therapy adoption.

The SLEEP 2026 data arrived after a period where Inspire Medical Systems has seen short term share price momentum pick up, with a 1 month share price return of 10.54% and a 7 day gain of 7.30%. This comes against a backdrop of a year to date share price decline of 50.45% and a 1 year total shareholder return decline of 65.47%, suggesting sentiment is rebounding from a much weaker longer term performance.

If this kind of clinical news has your attention, it can be useful to see what else is moving in related areas and compare potential opportunities through the lens of 39 healthcare AI stocks

After a sharp share price pullback and recent short term gains, Inspire Medical Systems now sits at a market value of about US$1.32b with some implied discount to analyst targets. This raises the question: is there genuine upside here, or is the market already pricing in future growth?

Most Popular Narrative: 12.4% Undervalued

Against the last close of $45.72, the most followed narrative on Inspire Medical Systems points to a fair value of about $52.17. It frames the recent SLEEP 2026 news in the context of reimbursement mechanics and long term earnings power.

The recent delay in transitioning centers to the Inspire V next-generation system, including slower onboarding, delayed SleepSync implementation, and the Medicare billing update, are transitory issues. As these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent up demand is realized.

Curious what sits behind that fair value gap for Inspire Medical Systems? The narrative leans heavily on changing revenue growth assumptions, slimmer profit margins, and a richer future earnings multiple that has to carry the entire valuation story.

Result: Fair Value of $52.17 (UNDERVALUED)

However, investors also need to weigh coding uncertainty for Inspire V, as well as the risk that higher marketing and expansion costs could continue to pressure margins if growth underwhelms.

Next Steps

If the mix of risks and rewards around Inspire Medical Systems feels finely balanced, do not wait on others to decide for you. Review the full picture through 3 key rewards and 2 important warning signs.

Looking for More Investment Ideas Beyond Inspire Medical Systems?

If Inspire Medical Systems is on your radar, now is a good moment to broaden your watchlist with other potential opportunities before the next wave of market moves.

• Spot potential value opportunities early by checking out 44 high quality undervalued stocks that combine attractive pricing with solid underlying metrics.
• Strengthen your portfolio’s foundations by reviewing the solid balance sheet and fundamentals stocks screener (48 results) that may better handle financial stress.
• Get ahead of the crowd by scanning the screener containing 19 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.